Skip to main content
. 2020 Aug 26;5(4):e000787. doi: 10.1136/esmoopen-2020-000787

Table 3.

Type of treatment in operable and locally advanced disease

Tumour extent Total
(n=86)
Locally advanced
(n=46)
Operable
(n=40)
N (%) N (%) N (%)
Type of treatment
 Neoadjuvant chemotherapy alone 10 (21.7) 0 (0.0) 10 (11.6)
 Neoadjuvant chemotherapy+surgery 13 (28.3) 9 (22.5) 22 (25.6)
 Neoadjuvant chemotherapy+radiotherapy* 4 (8.7) 0 (0.0) 4 (4.7)
 Surgery+adjuvant chemotherapy 2 (4.3) 11 (27.5) 13 (15.1)
 Neoadjuvant chemotherapy+surgery+adjuvant chemotherapy 6 (13.0) 6 (15.0) 12 (14.0)
 Neoadjuvant chemotherapy+radiotherapy+surgery* 3 (6.5) 1 (2.5) 4 (4.7)
 Neoadjuvant chemotherapy+surgery+radiotherapy 3 (6.5) 0 (0.0) 3 (3.5)
 Surgery+radiotherapy+adjuvant chemotherapy* 4 (8.7) 10 (25.0) 14 (16.3)
 Neoadjuvant chemotherapy+radiotherapy+surgery+adjuvant chemotherapy* 0 (0.0) 3 (7.5) 3 (3.5)
 Neoadjuvant chemotherapy+surgery+radiotherapy+adjuvant chemotherapy* 1 (2.2) 0 (0.0) 1 (1.2)

*Information on whether radiotherapy was administered concomitantly with (neo)adjuvant chemotherapy was not consistently collected.